Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system

Tetsuzo Tauchi, Masahiro Kizaki, Shinichiro Okamoto, Hideo Tanaka, Mitsune Tanimoto, Koiti Inokuchi, Tohru Murayama, Yoshio Saburi, Masayuki Hino, Mitsuru Tsudo, Taizo Shimomura, Yasushi Isobe, Kazuo Oshimi, Kazuo Dan, Kazuma Ohyashiki, Yasuo Ikeda

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The TARGET system is an online database that can be easily accessed by physicians. The registration of one's own chronic myeloid leukemia (CML) patients in the TARGET system makes it possible to share experiences among physicians, and, thus, may facilitate appropriate treatment for patients. Patients were registered in the TARGET system from October 2003 to March 2010 in Japan. A total of 1236 patients from 176 hospitals were registered in Japan. We analyzed data from 639 CML chronic phase patients not receiving prior therapy registered in this system. After 90 months follow-up, high survival rates were demonstrated for imatinib-treated newly diagnosed CML patients, with event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) rates of 79.1, 94.8, and 95.1%, respectively. A landmark analysis of 296 patients who showed a complete cytogenetic response (CCyR) at 12 months after the initiation of imatinib treatment revealed that, at 90 months, 99% of patients (95% CI, 98-100) had not progressed to accelerated phase (AP) or blastic crisis (BC). The patients showing a CCyR and a reduction of at least 3. log levels of BCR-ABL transcripts after 18 months of treatment had an estimated survival rate without CML progression of 100% at 84 months. The probability of achieving undetectable BCR-ABL in patients by 72 months with an major molecular response (MMR) at 12 months was 86.5%, compared with 64.7% for those without an MMR (p<0.0001). There were no new safety issues. In summary, based on this 7-year TARGET analysis, imatinib showed a continual clinical benefit as first-line therapy for newly diagnosed CML. The TARGET system may represent a more practical and general feature compared with the IRIS study.

Original languageEnglish
Pages (from-to)585-590
Number of pages6
JournalLeukemia Research
Volume35
Issue number5
DOIs
Publication statusPublished - 2011 May

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Survival Rate
Cytogenetics
Disease-Free Survival
Japan
Imatinib Mesylate
Leukemia, Myeloid, Chronic Phase
Online Systems
Physicians
Databases
Safety

Keywords

  • BCR-ABL
  • Chronic myelogenous leukemia
  • Imatinib

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. / Tauchi, Tetsuzo; Kizaki, Masahiro; Okamoto, Shinichiro; Tanaka, Hideo; Tanimoto, Mitsune; Inokuchi, Koiti; Murayama, Tohru; Saburi, Yoshio; Hino, Masayuki; Tsudo, Mitsuru; Shimomura, Taizo; Isobe, Yasushi; Oshimi, Kazuo; Dan, Kazuo; Ohyashiki, Kazuma; Ikeda, Yasuo.

In: Leukemia Research, Vol. 35, No. 5, 05.2011, p. 585-590.

Research output: Contribution to journalArticle

Tauchi, T, Kizaki, M, Okamoto, S, Tanaka, H, Tanimoto, M, Inokuchi, K, Murayama, T, Saburi, Y, Hino, M, Tsudo, M, Shimomura, T, Isobe, Y, Oshimi, K, Dan, K, Ohyashiki, K & Ikeda, Y 2011, 'Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system', Leukemia Research, vol. 35, no. 5, pp. 585-590. https://doi.org/10.1016/j.leukres.2010.10.027
Tauchi, Tetsuzo ; Kizaki, Masahiro ; Okamoto, Shinichiro ; Tanaka, Hideo ; Tanimoto, Mitsune ; Inokuchi, Koiti ; Murayama, Tohru ; Saburi, Yoshio ; Hino, Masayuki ; Tsudo, Mitsuru ; Shimomura, Taizo ; Isobe, Yasushi ; Oshimi, Kazuo ; Dan, Kazuo ; Ohyashiki, Kazuma ; Ikeda, Yasuo. / Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system. In: Leukemia Research. 2011 ; Vol. 35, No. 5. pp. 585-590.
@article{65dbcac0f7d349f4b7de37aec6693dfe,
title = "Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system",
abstract = "The TARGET system is an online database that can be easily accessed by physicians. The registration of one's own chronic myeloid leukemia (CML) patients in the TARGET system makes it possible to share experiences among physicians, and, thus, may facilitate appropriate treatment for patients. Patients were registered in the TARGET system from October 2003 to March 2010 in Japan. A total of 1236 patients from 176 hospitals were registered in Japan. We analyzed data from 639 CML chronic phase patients not receiving prior therapy registered in this system. After 90 months follow-up, high survival rates were demonstrated for imatinib-treated newly diagnosed CML patients, with event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) rates of 79.1, 94.8, and 95.1{\%}, respectively. A landmark analysis of 296 patients who showed a complete cytogenetic response (CCyR) at 12 months after the initiation of imatinib treatment revealed that, at 90 months, 99{\%} of patients (95{\%} CI, 98-100) had not progressed to accelerated phase (AP) or blastic crisis (BC). The patients showing a CCyR and a reduction of at least 3. log levels of BCR-ABL transcripts after 18 months of treatment had an estimated survival rate without CML progression of 100{\%} at 84 months. The probability of achieving undetectable BCR-ABL in patients by 72 months with an major molecular response (MMR) at 12 months was 86.5{\%}, compared with 64.7{\%} for those without an MMR (p<0.0001). There were no new safety issues. In summary, based on this 7-year TARGET analysis, imatinib showed a continual clinical benefit as first-line therapy for newly diagnosed CML. The TARGET system may represent a more practical and general feature compared with the IRIS study.",
keywords = "BCR-ABL, Chronic myelogenous leukemia, Imatinib",
author = "Tetsuzo Tauchi and Masahiro Kizaki and Shinichiro Okamoto and Hideo Tanaka and Mitsune Tanimoto and Koiti Inokuchi and Tohru Murayama and Yoshio Saburi and Masayuki Hino and Mitsuru Tsudo and Taizo Shimomura and Yasushi Isobe and Kazuo Oshimi and Kazuo Dan and Kazuma Ohyashiki and Yasuo Ikeda",
year = "2011",
month = "5",
doi = "10.1016/j.leukres.2010.10.027",
language = "English",
volume = "35",
pages = "585--590",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - Seven-year follow-up of patients receiving imatinib for the treatment of newly diagnosed chronic myelogenous leukemia by the TARGET system

AU - Tauchi, Tetsuzo

AU - Kizaki, Masahiro

AU - Okamoto, Shinichiro

AU - Tanaka, Hideo

AU - Tanimoto, Mitsune

AU - Inokuchi, Koiti

AU - Murayama, Tohru

AU - Saburi, Yoshio

AU - Hino, Masayuki

AU - Tsudo, Mitsuru

AU - Shimomura, Taizo

AU - Isobe, Yasushi

AU - Oshimi, Kazuo

AU - Dan, Kazuo

AU - Ohyashiki, Kazuma

AU - Ikeda, Yasuo

PY - 2011/5

Y1 - 2011/5

N2 - The TARGET system is an online database that can be easily accessed by physicians. The registration of one's own chronic myeloid leukemia (CML) patients in the TARGET system makes it possible to share experiences among physicians, and, thus, may facilitate appropriate treatment for patients. Patients were registered in the TARGET system from October 2003 to March 2010 in Japan. A total of 1236 patients from 176 hospitals were registered in Japan. We analyzed data from 639 CML chronic phase patients not receiving prior therapy registered in this system. After 90 months follow-up, high survival rates were demonstrated for imatinib-treated newly diagnosed CML patients, with event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) rates of 79.1, 94.8, and 95.1%, respectively. A landmark analysis of 296 patients who showed a complete cytogenetic response (CCyR) at 12 months after the initiation of imatinib treatment revealed that, at 90 months, 99% of patients (95% CI, 98-100) had not progressed to accelerated phase (AP) or blastic crisis (BC). The patients showing a CCyR and a reduction of at least 3. log levels of BCR-ABL transcripts after 18 months of treatment had an estimated survival rate without CML progression of 100% at 84 months. The probability of achieving undetectable BCR-ABL in patients by 72 months with an major molecular response (MMR) at 12 months was 86.5%, compared with 64.7% for those without an MMR (p<0.0001). There were no new safety issues. In summary, based on this 7-year TARGET analysis, imatinib showed a continual clinical benefit as first-line therapy for newly diagnosed CML. The TARGET system may represent a more practical and general feature compared with the IRIS study.

AB - The TARGET system is an online database that can be easily accessed by physicians. The registration of one's own chronic myeloid leukemia (CML) patients in the TARGET system makes it possible to share experiences among physicians, and, thus, may facilitate appropriate treatment for patients. Patients were registered in the TARGET system from October 2003 to March 2010 in Japan. A total of 1236 patients from 176 hospitals were registered in Japan. We analyzed data from 639 CML chronic phase patients not receiving prior therapy registered in this system. After 90 months follow-up, high survival rates were demonstrated for imatinib-treated newly diagnosed CML patients, with event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) rates of 79.1, 94.8, and 95.1%, respectively. A landmark analysis of 296 patients who showed a complete cytogenetic response (CCyR) at 12 months after the initiation of imatinib treatment revealed that, at 90 months, 99% of patients (95% CI, 98-100) had not progressed to accelerated phase (AP) or blastic crisis (BC). The patients showing a CCyR and a reduction of at least 3. log levels of BCR-ABL transcripts after 18 months of treatment had an estimated survival rate without CML progression of 100% at 84 months. The probability of achieving undetectable BCR-ABL in patients by 72 months with an major molecular response (MMR) at 12 months was 86.5%, compared with 64.7% for those without an MMR (p<0.0001). There were no new safety issues. In summary, based on this 7-year TARGET analysis, imatinib showed a continual clinical benefit as first-line therapy for newly diagnosed CML. The TARGET system may represent a more practical and general feature compared with the IRIS study.

KW - BCR-ABL

KW - Chronic myelogenous leukemia

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=79954592021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954592021&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2010.10.027

DO - 10.1016/j.leukres.2010.10.027

M3 - Article

C2 - 21145591

AN - SCOPUS:79954592021

VL - 35

SP - 585

EP - 590

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 5

ER -